Papadimitriou A, Urena M, Hamill G, Stanhope R, Leiper A D
Department of Growth and Development, Institute of Child Health, London.
Arch Dis Child. 1991 Jun;66(6):689-92. doi: 10.1136/adc.66.6.689.
Growth hormone was given to 13 children (nine boys, four girls) with acute leukaemia who had undergone treatment with cyclophosphamide and total body irradiation before bone marrow transplantation. Mean age at total body irradiation and bone marrow transplantation was 9.0 years (range 3.7-15.8). Endocrinological investigation was carried out at a mean of 2.0 years (range 0.4-4.0) after bone marrow transplantation. Peak serum growth hormone responses to hypoglycaemia were less than 10.0 micrograms/l (less than 20.0 mU/l) in 10, 10.5 micrograms/l (21.0 mU/l) in one, greater than 16.0 micrograms/l (greater than 32.0 mU/l) in two patients. Mean age of the patients at the start of growth hormone treatment was 12.2 years (range 5.8-18.2). The mean time between total body irradiation and bone marrow transplantation and the start of growth hormone treatment was 3.2 years (range, 1.1-5.0). Height velocity SD score (SD) increased from a mean pretreatment value of -1.27 (0.65) to + 0.22 (0.81) in the first year, +0.16 (1.11) in the second year, and +0.42 (0.71) in the third year of treatment. Height SD score (SD) changed only slightly from -1.52 (0.42) to -1.50 (0.47) in the first year, to -1.50 (0.46) in the second year, and -1.74 (0.92) in the third year. Measurement of segmental proportions showed no significant increase in subischial leg length from -0.87 (0.67) to -0.63 (0.65) in the first year, to -0.58 (0.70) in the second year, and -0.80 (1.14) in the third year of treatment. Our data indicate that children who have undergone total body irradiation and bone marrow transplantation respond to treatment with growth hormone in either of two dose regimens, with an increase in height velocity that is adequate to restore a normal growth rate but not to 'catch up', and that total body irradiation impairs not only spinal but also leg growth, possibly by a direct effect of irradiation on the epiphyses and soft tissues.
对13名患有急性白血病的儿童(9名男孩,4名女孩)给予生长激素治疗,这些儿童在骨髓移植前接受了环磷酰胺和全身照射治疗。全身照射和骨髓移植时的平均年龄为9.0岁(范围3.7 - 15.8岁)。在骨髓移植后平均2.0年(范围0.4 - 4.0年)进行了内分泌学检查。10名患者对低血糖的血清生长激素峰值反应低于10.0微克/升(低于20.0毫单位/升),1名患者为10.5微克/升(21.0毫单位/升),2名患者大于16.0微克/升(大于32.0毫单位/升)。开始生长激素治疗时患者的平均年龄为12.2岁(范围5.8 - 18.2岁)。全身照射与骨髓移植以及开始生长激素治疗之间的平均时间为3.2年(范围1.1 - 5.0年)。治疗第一年身高速度标准差评分(SD)从治疗前的平均-1.27(0.65)增加到+0.22(0.81),第二年为+0.16(1.11),第三年为+0.42(0.71)。身高标准差评分(SD)在第一年仅从-1.52(0.42)略有变化至-1.50(0.47),第二年为-1.50(0.46),第三年为-1.74(0.92)。节段比例测量显示,治疗第一年坐骨下腿长从-0.87(0.67)至-0.63(0.65)无显著增加,第二年为-0.58(0.70),第三年为-0.80(1.14)。我们的数据表明,接受过全身照射和骨髓移植的儿童对两种剂量方案的生长激素治疗均有反应,身高速度增加足以恢复正常生长速度,但无法“追赶”生长,且全身照射不仅损害脊柱生长,还损害腿部生长,可能是由于照射对骨骺和软组织的直接作用。